Clinical Trials

90 enrolled

Small Cell Lung Carcinoma

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

30 enrolled

Non Small Cell Lung Cancer Recurrent

NCT04895930 2023-01-06

FOCUS-A

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

42 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05387109 2022-05-24

pcwaintrl

Phase 4 Unknown

41 enrolled

NSCLC

NCT04660097 2022-04-12

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

120 enrolled

Small Cell Lung Carcinoma

NCT04325763 2022-03-31

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Phase 3 Unknown

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05218759 2022-02-01

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04797806 2021-03-15

SAINT

Phase 3 Unknown

206 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

25 enrolled

Small Cell Lung Carcinoma

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04273815 2020-07-08

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Phase 1/2 Unknown

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled

Small Cell Lung Carcinoma

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

33 enrolled

Small Cell Lung Carcinoma

NCT03624309 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03700359 2019-11-29

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

60 enrolled

Small Cell Lung Carcinoma

NCT04164745 2019-11-15

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

49 enrolled

NSCLC

NCT03910127 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03769805 2019-10-22

CSOAIMTOAN

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04073550 2019-08-29

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

Phase 3 Unknown

184 enrolled

Small Cell Lung Carcinoma

NCT03841136 2019-03-28

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

70 enrolled

Small Cell Lung Carcinoma

NCT03799601 2019-01-10

ALTER-L013

Phase 4 Unknown

45 enrolled

NSCLC

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

30 enrolled

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03778138 2018-12-19

ALTER-L025

51 enrolled

Non-squamous Cell Non-Small Cell Lung Cancer

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

20 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03732846 2018-11-07

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

43 enrolled

Small Cell Lung Carcinoma

NCT03728374 2018-11-02

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03671538 2018-09-17

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

62 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT03654027 2018-08-31

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

9 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT03589950 2018-07-18

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

60 enrolled

Lung Neoplasms

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

110 enrolled